Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma
Transarterial chemoembolization (TACE) is widely acknowledged as the first-line therapeutic strategy for hepatocellular carcinoma (HCC), one of the most common malignant tumors of the liver. Despite its established efficacy, the responses of TACE are subject to significant variability due to the inh...
Gespeichert in:
Veröffentlicht in: | Radiology of Infectious Diseases 2023-09, Vol.10 (3), p.93-103 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 103 |
---|---|
container_issue | 3 |
container_start_page | 93 |
container_title | Radiology of Infectious Diseases |
container_volume | 10 |
creator | Wang, Dandan Zhang, Jinfeng Jiang, Huijie |
description | Transarterial chemoembolization (TACE) is widely acknowledged as the first-line therapeutic strategy for hepatocellular carcinoma (HCC), one of the most common malignant tumors of the liver. Despite its established efficacy, the responses of TACE are subject to significant variability due to the inherent tumor heterogeneity and patient-specific physiological and genetic factors. This creates a challenge in treatment standardization and demands a tailored approach for each patient. What’s more, multiple TACE sessions are often required, particularly for larger tumors. However, redundant repeated treatments without proper patient selection may lead to TACE resistance or liver function damage, potentially foreclosing other therapeutic options. This clinical landscape underscores the pressing need for developing precise and minimally invasive tools for predicting TACE efficacy. Biomarkers are emerging as particularly promising tools in this context. Defined as quantifiable variables, biomarkers can be objectively measured to reflect the biological impact of treatment or exposure, which is widely employed in disease diagnosis, monitoring, curative effect evaluation, prognosis prediction, and drug development. In this review, we delve into the current research progression on predictive biomarkers for TACE efficacy. These include standard laboratory tests, advanced imaging techniques, and emerging technologies such as liquid biopsy and artificial intelligence (AI). Laboratory assays may involve measuring liver function or cancer markers, while imaging studies can offer insights into tumor size and metabolic activity. Liquid biopsy captures circulating tumor DNA to provide real-time information, and AI applications have begun to offer more nuanced predictive analytics. Looking to the future, the incorporation of big data and multi-omics studies could revolutionize the field. These integrative analyses promise to refine the existing predictive models for TACE efficacy, enabling more personalized and effective treatment strategies for patients suffering from HCC. As we move forward, these advancements will undoubtedly have a profound impact on clinical decision-making processes, ultimately improving patient outcomes. |
doi_str_mv | 10.4103/rid.RID-D-23-00005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3132559090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3132559090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1155-5acd2ec5824f885cca1c0730979c7d8301e606ddf8434864b8d6e5ea6b4da1423</originalsourceid><addsrcrecordid>eNo9kEtLAzEUhYMoWGr_gKuA66l5zmSW0vooFARRcBcyyQ2NzkzGZFqov97xgXdz7uJwDudD6JKSpaCEX6fglk-bdbEuGC_IdPIEzRiXrCgZez39_yk9R4ucQ0Mkr0hVKzFD3RoO0Mahg37E0eMhgQt2DAfATYidSe-QMvYx4TGZPps0QgqmxXYHXYSuiW34NGOIPQbvgzX2iEOPdzCYMVpo231rErYm2dBPaRfozJs2w-JP5-jl7vZ59VBsH-83q5ttYSmVspDGOgZWKia8UtJaQy2pOKmr2lZOcUKhJKVzXgkuVCka5UqQYMpGOEMF43N09Zs7pPixhzzqt7hP_VSpOeVMyprUZHKxX5dNMecEXg8pTJOPmhL9TVZPZPVEVq814_qHLP8CRUpvww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132559090</pqid></control><display><type>article</type><title>Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma</title><source>Medknow Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Wang, Dandan ; Zhang, Jinfeng ; Jiang, Huijie</creator><creatorcontrib>Wang, Dandan ; Zhang, Jinfeng ; Jiang, Huijie</creatorcontrib><description>Transarterial chemoembolization (TACE) is widely acknowledged as the first-line therapeutic strategy for hepatocellular carcinoma (HCC), one of the most common malignant tumors of the liver. Despite its established efficacy, the responses of TACE are subject to significant variability due to the inherent tumor heterogeneity and patient-specific physiological and genetic factors. This creates a challenge in treatment standardization and demands a tailored approach for each patient. What’s more, multiple TACE sessions are often required, particularly for larger tumors. However, redundant repeated treatments without proper patient selection may lead to TACE resistance or liver function damage, potentially foreclosing other therapeutic options. This clinical landscape underscores the pressing need for developing precise and minimally invasive tools for predicting TACE efficacy. Biomarkers are emerging as particularly promising tools in this context. Defined as quantifiable variables, biomarkers can be objectively measured to reflect the biological impact of treatment or exposure, which is widely employed in disease diagnosis, monitoring, curative effect evaluation, prognosis prediction, and drug development. In this review, we delve into the current research progression on predictive biomarkers for TACE efficacy. These include standard laboratory tests, advanced imaging techniques, and emerging technologies such as liquid biopsy and artificial intelligence (AI). Laboratory assays may involve measuring liver function or cancer markers, while imaging studies can offer insights into tumor size and metabolic activity. Liquid biopsy captures circulating tumor DNA to provide real-time information, and AI applications have begun to offer more nuanced predictive analytics. Looking to the future, the incorporation of big data and multi-omics studies could revolutionize the field. These integrative analyses promise to refine the existing predictive models for TACE efficacy, enabling more personalized and effective treatment strategies for patients suffering from HCC. As we move forward, these advancements will undoubtedly have a profound impact on clinical decision-making processes, ultimately improving patient outcomes.</description><identifier>ISSN: 2352-6211</identifier><identifier>EISSN: 2352-622X</identifier><identifier>DOI: 10.4103/rid.RID-D-23-00005</identifier><language>eng</language><publisher>Beijing: Medknow Publications & Media Pvt. Ltd</publisher><subject>Biomarkers ; Biopsy ; Chemoembolization ; Liver cancer ; Tumors</subject><ispartof>Radiology of Infectious Diseases, 2023-09, Vol.10 (3), p.93-103</ispartof><rights>2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1155-5acd2ec5824f885cca1c0730979c7d8301e606ddf8434864b8d6e5ea6b4da1423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Wang, Dandan</creatorcontrib><creatorcontrib>Zhang, Jinfeng</creatorcontrib><creatorcontrib>Jiang, Huijie</creatorcontrib><title>Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma</title><title>Radiology of Infectious Diseases</title><description>Transarterial chemoembolization (TACE) is widely acknowledged as the first-line therapeutic strategy for hepatocellular carcinoma (HCC), one of the most common malignant tumors of the liver. Despite its established efficacy, the responses of TACE are subject to significant variability due to the inherent tumor heterogeneity and patient-specific physiological and genetic factors. This creates a challenge in treatment standardization and demands a tailored approach for each patient. What’s more, multiple TACE sessions are often required, particularly for larger tumors. However, redundant repeated treatments without proper patient selection may lead to TACE resistance or liver function damage, potentially foreclosing other therapeutic options. This clinical landscape underscores the pressing need for developing precise and minimally invasive tools for predicting TACE efficacy. Biomarkers are emerging as particularly promising tools in this context. Defined as quantifiable variables, biomarkers can be objectively measured to reflect the biological impact of treatment or exposure, which is widely employed in disease diagnosis, monitoring, curative effect evaluation, prognosis prediction, and drug development. In this review, we delve into the current research progression on predictive biomarkers for TACE efficacy. These include standard laboratory tests, advanced imaging techniques, and emerging technologies such as liquid biopsy and artificial intelligence (AI). Laboratory assays may involve measuring liver function or cancer markers, while imaging studies can offer insights into tumor size and metabolic activity. Liquid biopsy captures circulating tumor DNA to provide real-time information, and AI applications have begun to offer more nuanced predictive analytics. Looking to the future, the incorporation of big data and multi-omics studies could revolutionize the field. These integrative analyses promise to refine the existing predictive models for TACE efficacy, enabling more personalized and effective treatment strategies for patients suffering from HCC. As we move forward, these advancements will undoubtedly have a profound impact on clinical decision-making processes, ultimately improving patient outcomes.</description><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Chemoembolization</subject><subject>Liver cancer</subject><subject>Tumors</subject><issn>2352-6211</issn><issn>2352-622X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLAzEUhYMoWGr_gKuA66l5zmSW0vooFARRcBcyyQ2NzkzGZFqov97xgXdz7uJwDudD6JKSpaCEX6fglk-bdbEuGC_IdPIEzRiXrCgZez39_yk9R4ucQ0Mkr0hVKzFD3RoO0Mahg37E0eMhgQt2DAfATYidSe-QMvYx4TGZPps0QgqmxXYHXYSuiW34NGOIPQbvgzX2iEOPdzCYMVpo231rErYm2dBPaRfozJs2w-JP5-jl7vZ59VBsH-83q5ttYSmVspDGOgZWKia8UtJaQy2pOKmr2lZOcUKhJKVzXgkuVCka5UqQYMpGOEMF43N09Zs7pPixhzzqt7hP_VSpOeVMyprUZHKxX5dNMecEXg8pTJOPmhL9TVZPZPVEVq814_qHLP8CRUpvww</recordid><startdate>202309</startdate><enddate>202309</enddate><creator>Wang, Dandan</creator><creator>Zhang, Jinfeng</creator><creator>Jiang, Huijie</creator><general>Medknow Publications & Media Pvt. Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>202309</creationdate><title>Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma</title><author>Wang, Dandan ; Zhang, Jinfeng ; Jiang, Huijie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1155-5acd2ec5824f885cca1c0730979c7d8301e606ddf8434864b8d6e5ea6b4da1423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Chemoembolization</topic><topic>Liver cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Dandan</creatorcontrib><creatorcontrib>Zhang, Jinfeng</creatorcontrib><creatorcontrib>Jiang, Huijie</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Radiology of Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Dandan</au><au>Zhang, Jinfeng</au><au>Jiang, Huijie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma</atitle><jtitle>Radiology of Infectious Diseases</jtitle><date>2023-09</date><risdate>2023</risdate><volume>10</volume><issue>3</issue><spage>93</spage><epage>103</epage><pages>93-103</pages><issn>2352-6211</issn><eissn>2352-622X</eissn><abstract>Transarterial chemoembolization (TACE) is widely acknowledged as the first-line therapeutic strategy for hepatocellular carcinoma (HCC), one of the most common malignant tumors of the liver. Despite its established efficacy, the responses of TACE are subject to significant variability due to the inherent tumor heterogeneity and patient-specific physiological and genetic factors. This creates a challenge in treatment standardization and demands a tailored approach for each patient. What’s more, multiple TACE sessions are often required, particularly for larger tumors. However, redundant repeated treatments without proper patient selection may lead to TACE resistance or liver function damage, potentially foreclosing other therapeutic options. This clinical landscape underscores the pressing need for developing precise and minimally invasive tools for predicting TACE efficacy. Biomarkers are emerging as particularly promising tools in this context. Defined as quantifiable variables, biomarkers can be objectively measured to reflect the biological impact of treatment or exposure, which is widely employed in disease diagnosis, monitoring, curative effect evaluation, prognosis prediction, and drug development. In this review, we delve into the current research progression on predictive biomarkers for TACE efficacy. These include standard laboratory tests, advanced imaging techniques, and emerging technologies such as liquid biopsy and artificial intelligence (AI). Laboratory assays may involve measuring liver function or cancer markers, while imaging studies can offer insights into tumor size and metabolic activity. Liquid biopsy captures circulating tumor DNA to provide real-time information, and AI applications have begun to offer more nuanced predictive analytics. Looking to the future, the incorporation of big data and multi-omics studies could revolutionize the field. These integrative analyses promise to refine the existing predictive models for TACE efficacy, enabling more personalized and effective treatment strategies for patients suffering from HCC. As we move forward, these advancements will undoubtedly have a profound impact on clinical decision-making processes, ultimately improving patient outcomes.</abstract><cop>Beijing</cop><pub>Medknow Publications & Media Pvt. Ltd</pub><doi>10.4103/rid.RID-D-23-00005</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2352-6211 |
ispartof | Radiology of Infectious Diseases, 2023-09, Vol.10 (3), p.93-103 |
issn | 2352-6211 2352-622X |
language | eng |
recordid | cdi_proquest_journals_3132559090 |
source | Medknow Open Access Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Biomarkers Biopsy Chemoembolization Liver cancer Tumors |
title | Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A29%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20predictive%20biomarkers%20for%20transarterial%20chemoembolization%20efficacy%20in%20hepatocellular%20carcinoma&rft.jtitle=Radiology%20of%20Infectious%20Diseases&rft.au=Wang,%20Dandan&rft.date=2023-09&rft.volume=10&rft.issue=3&rft.spage=93&rft.epage=103&rft.pages=93-103&rft.issn=2352-6211&rft.eissn=2352-622X&rft_id=info:doi/10.4103/rid.RID-D-23-00005&rft_dat=%3Cproquest_cross%3E3132559090%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3132559090&rft_id=info:pmid/&rfr_iscdi=true |